The U.S. Centers for Medicare and Medicaid Services indefinitely delayed a voluntary Medicare model intended to cover obesity drugs under its BALANCE framework, and instead extended a temporary GLP-1 Bridge demonstration through the end of 2027. The decision followed payer responses that indicated they would not take up the program. The change pauses a central component of the policy push to bring manufacturer-priced obesity medications into Medicare coverage pathways. Medicaid participation depends on whether states opt in, while the Medicare component is now deferred. For obesity-focused biopharma, the delay extends uncertainty around real-world formulary reach and reimbursement timelines, even as GLP-1 uptake continues across commercial insurance.